There is no medicine whose purpose is to lower creatinine. None exists, none is in development, and any product sold on that promise is either misunderstanding what creatinine is or counting on you to misunderstand it. What does exist is a set of medicines that protect kidney function, and when they work, the creatinine stops climbing or settles. That is a different thing, and the difference is the whole point of this page.
Ask a kidney specialist for the best medicine to reduce creatinine and you will get a careful pause, because the honest answer is that the question has the wrong shape. Creatinine is a waste product your muscles make at a steady rate. Its level in the blood is a readout of how well your kidneys clear it. A drug that pushed the number down without changing the filtering would be worse than useless, because it would hide the problem. What kidney doctors actually prescribe are medicines that lower the pressure inside the filtering units, cut protein leak, control blood glucose and blood pressure, and blunt the inflammation and scarring that drive kidney disease forward. Those drugs earn their place by protecting function over years. The creatinine follows, or at least stops getting worse.
What follows describes those medicines at the level of drug classes: what they are, how they work, what the trial evidence supports, and where the honest uncertainty sits. It gives no doses and no instruction to start or stop anything, because prescribing depends on your kidney function, your other conditions, your potassium, your blood pressure and the rest of your medication list. Only the clinician holding all of that can make the decision. For the wider picture, what causes high creatinine levels explains why the number rose in the first place, and how high creatinine is treated covers the broader management plan this page sits inside.
What creatinine is explains the molecule in plain terms. To convert your own result into an estimated filtration rate, use the Waldev creatinine clearance calculator. That estimate, not the raw creatinine, is what treatment decisions actually track.
On this page
Why there is no medicine designed to lower creatinine
Drugs get developed against targets that matter. Nobody has developed one against creatinine because creatinine does almost nothing. It is inert. At the concentrations seen in kidney disease it is not toxic, it does not damage tissue, and it does not cause the symptoms people attribute to it. Around 95 percent of the body’s creatine pool sits in skeletal muscle, a small fixed fraction converts to creatinine each day through a spontaneous chemical reaction, and the kidneys clear it. That is the entire story.
Doctors measure it for one reason. It is cheap, stable and it tracks filtration reasonably well. If a better everyday marker existed, creatinine would be dropped tomorrow, and in some situations cystatin C is already used alongside it for exactly that reason. The number is a proxy. Treating a proxy is like fixing a fever by cooling the thermometer.
Consider what a genuine creatinine-lowering drug would have to do. It could suppress production, which would mean interfering with muscle metabolism or reducing muscle mass. Serious illness and wasting already do that, and the low creatinine that results is a bad sign rather than a good one. It could block the reaction converting creatine to creatinine, which no drug does and which would achieve nothing clinically. Or it could strip creatinine from blood by some route other than the kidney, which is essentially what dialysis does, and dialysis is not a medicine.
A drug that lowered creatinine while filtration stayed the same or got worse would be actively dangerous. It would delay diagnosis, mask deterioration, and lead to wrong dosing of every medicine adjusted by kidney function. That is not a theoretical objection. It is why the treatment goal is written the way it is in every kidney guideline in the world.
The distinction that everything else depends on
Two people can have identical creatinine results and completely different situations. A 34-year-old powerlifter with a creatinine of 1.4 mg/dL and a clean urine test has more muscle, more production and entirely healthy kidneys. A 78-year-old woman with the same 1.4 and very little muscle may have lost more than half her filtration. The number is the same. The meaning is not remotely the same, and no drug could sensibly be aimed at the number they share.
What clinicians actually track are four things, and none of them is raw creatinine on its own.
Estimated filtration rate
Creatinine adjusted for age and sex, giving eGFR. This is the working measure of kidney function and what the stages of kidney disease are defined by. A treatment that flattens the eGFR decline is succeeding even if the creatinine never falls.
Protein or albumin in the urine
Albuminuria is both a sign of glomerular damage and an independent driver of further scarring. Several of the most effective kidney drugs are judged largely on how much they reduce it, long before any effect on creatinine appears.
The slope over time
Not one value but the trend across years. A creatinine drifting up by a fraction annually and one climbing steeply describe very different futures, and treatment aims to bend that line flatter.
The cause underneath
Diabetes, hypertension, obstruction, an autoimmune disease, a medication. What gets prescribed depends far more on this than on how high the number happens to be.
Hold those four in mind and the marketing collapses on contact. A product claiming to lower creatinine says nothing about eGFR slope, nothing about albuminuria, nothing about the cause. Even if it did shift the number, you would have no way of knowing whether anything useful had happened. The National Kidney Foundation’s explanation of eGFR sets out why filtration estimates rather than creatinine alone are what treatment is judged against. If your own result needs putting in context, what a normal creatinine level looks like and what high creatinine means cover the interpretation.
ACE inhibitors and ARBs: the oldest protective class
These are the drugs most people with kidney disease and protein in the urine end up taking, and they have held that position for three decades because the evidence behind them is unusually strong.
Names you may recognise in the ACE inhibitor group include ramipril, lisinopril, enalapril and perindopril. The angiotensin receptor blockers, usually shortened to ARBs, include losartan, irbesartan, candesartan, valsartan and telmisartan. They act on the same hormonal system from slightly different angles, and in practice one or the other is used, never both together, because the combination increases harm without adding benefit.
The mechanism, and why it matters here
Each filtering unit in the kidney has a vessel bringing blood in and a vessel taking blood out. Angiotensin II constricts the outgoing vessel more than the incoming one, raising the pressure inside the filter. In the short term that maintains filtration. Over years, the elevated pressure is itself damaging. It pushes protein through the filter membrane, and protein passing along the tubules provokes inflammation and scarring. Blocking the system relaxes the outgoing vessel, lowers the pressure inside the filter, and reduces the protein leak.
That is why these are described as kidney-protective drugs rather than blood pressure drugs when used this way. The protection is only partly explained by the fall in systemic blood pressure. Landmark randomised trials in diabetic kidney disease during the 1990s and early 2000s showed slower progression towards kidney failure than the blood pressure effect alone would predict, and that finding reshaped practice worldwide.
What they do to the creatinine number
Here is the part that confuses people. Lowering the pressure inside the filter reduces filtration slightly, so creatinine usually rises a little when these drugs are started or the dose is increased. Typically it is a modest rise that then settles. That rise is expected. It is a sign the drug is doing precisely what it was prescribed to do. Stopping the drug because the creatinine went up is one of the more common and more damaging misunderstandings in this whole area, and it is a decision that should never be made without the prescriber.
There are limits, which is where clinical judgement stops being optional. A large or continuing rise, as opposed to a small one that plateaus, needs investigating and can point to narrowed kidney arteries or dehydration. Potassium can climb on these drugs and requires monitoring. During an acute illness with vomiting, diarrhoea or poor fluid intake they are often paused temporarily, which is the reasoning behind the sick-day rules many kidney patients are given. None of that is something to work out alone.
SGLT2 inhibitors: the most significant addition in decades
Dapagliflozin, empagliflozin and canagliflozin were developed as diabetes drugs. They turned out to be considerably more useful for the kidney and the heart than for glucose, and their arrival changed kidney medicine more than anything since the ACE inhibitors.
They block a transporter in the kidney tubule that reabsorbs glucose and sodium from the filtrate. Glucose is lost in the urine, which lowers blood sugar modestly. The kidney benefit comes mainly from the sodium. More sodium reaching a sensing structure further along the tubule triggers a reflex that constricts the incoming vessel, lowering the pressure inside the filter. It is a different route to the same protective result as the ACE inhibitors, which is broadly why the two classes add to each other rather than duplicating each other.
Large randomised trials in chronic kidney disease, including populations with and without diabetes, have shown reduced risk of kidney disease progression, of reaching kidney failure, and of death from kidney or cardiovascular causes. Guidelines now recommend the class widely in chronic kidney disease with albuminuria, not only in diabetes. For a kidney drug, that is an unusually decisive body of evidence.
They produce the same counterintuitive early signal as the previous class: a small dip in eGFR and a small rise in creatinine over the first weeks, which then plateaus and partly reverses across the following months, with a flatter long-term slope than without the drug. Judging these medicines on a blood test taken a fortnight after starting them would lead you to exactly the wrong conclusion.
The side effects are real and worth stating rather than glossing over. Genital and urinary fungal infections are more common. Volume depletion can occur, particularly alongside a diuretic. Diabetic ketoacidosis can develop at near-normal glucose levels in people with diabetes, which is why anyone taking one is told which symptoms to report and when the drug should be held around surgery or acute illness. Whether the class suits you depends on your kidney function and your other conditions, and that assessment belongs to your own doctor.
Non-steroidal mineralocorticoid receptor antagonists
Finerenone is the drug most people mean here. It blocks the mineralocorticoid receptor, the same receptor targeted by the older agents spironolactone and eplerenone, but with a different chemical structure and a different distribution across tissues.
Overactivation of that receptor drives inflammation and fibrosis in the kidney and heart, a separate pathway from the pressure effects the previous two classes act on. Blocking it reduces albuminuria, and in large randomised trials in chronic kidney disease associated with type 2 diabetes it slowed progression and reduced cardiovascular events on top of standard treatment with a renin-angiotensin blocker.
The obvious limitation is potassium. Blocking this receptor raises potassium, sometimes to dangerous levels, and the risk is higher when kidney function is already reduced or when the person also takes an ACE inhibitor or ARB. Anyone prescribed one is monitored with blood tests on a defined schedule, and the drug does not suit everyone. The older steroidal agents in the class carry the same potassium risk plus hormonal effects such as breast tenderness in men, which is part of why the newer drug was developed at all.
This class illustrates something worth holding on to. Its benefit shows up as fewer people reaching kidney failure over a period of years. It does not show up as a satisfying drop in this month’s creatinine, and expecting that would be misreading what the drug is for.
GLP-1 receptor agonists, where they apply
Semaglutide, dulaglutide and liraglutide belong to a class developed for type 2 diabetes and now widely used for obesity. Kidney outcome data has accumulated steadily, and a large dedicated trial in people with type 2 diabetes and chronic kidney disease reported a reduced risk of major kidney events, which moved this class from interesting to genuinely relevant.
The mechanisms probably overlap. Better glucose control, substantial weight loss, lower blood pressure, reduced albuminuria and direct anti-inflammatory effects on kidney tissue have all been proposed. Untangling which contributes most is still an open question, and it is honest to say so rather than pretend the picture is settled.
The class is not a general kidney drug in the way the previous three are. Its established kidney role sits within type 2 diabetes, and how far it extends to kidney disease from other causes is much less certain. Gastrointestinal side effects are common, and dehydration from vomiting or diarrhoea can itself raise creatinine, which is a practical thing to mention to whoever prescribes it.
Statins: for the heart, not for the creatinine
Statins appear on almost every kidney patient’s medication list, and the reason is not the kidney. People with chronic kidney disease are far more likely to die of cardiovascular disease than to reach dialysis, and that risk climbs steadily as filtration falls. Lowering cholesterol addresses the thing most likely to actually harm them.
Evidence for slowing kidney disease itself is much weaker, and anyone telling you a statin will bring your creatinine down is overselling badly. A large trial of cholesterol lowering in chronic kidney disease showed clear reductions in atherosclerotic events with no convincing effect on progression to kidney failure. Trials in people already on dialysis largely failed to show cardiovascular benefit, which is why statins are usually not started fresh at that stage, although they are often continued if someone is already established on one.
One caution belongs here. Statins can rarely cause muscle breakdown, and severe muscle breakdown releases both creatinine and myoglobin, raising the number by two routes while injuring the kidney directly. Unexplained severe muscle pain and weakness with dark urine in someone taking a statin is an urgent problem, not a wait-and-see one.
Treating the cause is the actual treatment
The protective classes above are generic. They apply across a great deal of kidney disease. But the largest single determinant of what happens to your kidney function is whether the thing damaging it is being dealt with, and that is specific to you.
| Underlying cause | What treatment is aimed at | Realistic effect on creatinine |
|---|---|---|
| Type 2 diabetes | Glucose control plus the protective classes above; weight and blood pressure management | Slows the rise; will not reverse established scarring |
| High blood pressure | Reaching an individualised target, usually with a renin-angiotensin blocker in the regimen | Among the most effective ways to flatten the slope |
| Obstruction (stones, prostate, stricture) | Relieving the blockage with a catheter, stent or surgery | Can fall substantially within days if relieved early |
| Glomerulonephritis | Immunosuppression targeted to the specific diagnosis, usually after a biopsy | Can genuinely improve if inflammation is controlled before scarring sets in |
| Lupus nephritis | Specialist immunosuppressive regimens | Improvement is possible when remission is achieved |
| Drug-induced injury | Identifying and withdrawing the responsible drug, under supervision | Often reverses over days to weeks |
| Dehydration or reduced blood flow | Restoring volume; treating heart failure or infection | Usually corrects quickly and fairly completely |
| Myeloma or amyloidosis | Haematology treatment of the underlying disease | Kidney function tracks the response of the primary disease |
| Polycystic kidney disease | Tolvaptan in selected rapidly progressing cases; blood pressure control | Slows cyst growth and functional decline; does not reverse |
Two rows deserve emphasis. Obstruction and drug-induced injury are the causes where the number can genuinely come down, sometimes dramatically, and both are found by asking rather than by treating blindly. An ultrasound and a careful medication review resolve a large share of unexplained rises between them. Medications that raise creatinine goes through that review in detail.
The medicines that raise creatinine and are still the right treatment
This is the section that most undermines the idea of chasing the number, and it deserves its own space because it catches out patients and, occasionally, clinicians who do not work in kidney medicine.
Several of the best kidney drugs cause a small rise in creatinine when they are started. Not as a side effect to be tolerated, but as a direct consequence of the mechanism that makes them protective. They reduce the pressure inside the filtering unit. Lower pressure means slightly less filtration in the short term, so creatinine ticks up. What they buy in exchange is less protein forced through the membrane, less inflammation along the tubules, and less scarring over the following decade.
A person watching only the creatinine sees the drug make things worse. A person watching the ten-year outcome sees the opposite. Both are looking at the same patient.
| Drug class | What happens early | What happens long term |
|---|---|---|
| ACE inhibitors and ARBs | Small creatinine rise within one to two weeks, then a plateau | Slower decline in filtration; less protein in urine; fewer people reaching kidney failure |
| SGLT2 inhibitors | An eGFR dip over the first weeks, largest early | Dip recovers partly and the long-term slope is flatter than without the drug |
| Diuretics in heart failure | Creatinine can rise as fluid is removed | Symptom relief and survival benefit; the rise is often accepted deliberately |
| Non-steroidal MRAs | Small early creatinine change; potassium needs watching | Reduced albuminuria and slower progression on top of existing treatment |
The distinction a clinician makes is between an expected rise and a worrying one. An expected rise is modest, appears soon after starting or increasing the drug, and then stops. A worrying rise is large, keeps going, or comes with falling urine output, new swelling, breathlessness or confusion. The second pattern needs assessment quickly. The first usually needs nothing but a repeat blood test at the interval your doctor sets.
Some drugs raise the measured creatinine without touching filtration at all, which is a third pattern again. Trimethoprim, cimetidine, cobicistat, dolutegravir and fenofibrate all block the tubular route by which a portion of creatinine leaves the body, or interfere with the assay. The kidney filters exactly as well as it did last month; the number simply reads higher. Doctors who know the drug was started expect the bump and do not chase it.
None of this is a reason to second-guess your own prescription. It is a reason to ask what a given medicine is expected to do to your results, and over what timescale, so that a predicted change does not get mistaken for a deterioration. That conversation is worth having at the appointment where the drug is first suggested.
Medicines that treat the consequences rather than the marker
A large part of what gets prescribed in kidney disease has nothing to do with slowing progression and nothing to do with creatinine. It treats the downstream problems that appear as filtration falls, and these medicines matter because those problems are what make people feel unwell and what shortens lives.
Phosphate binders
Damaged kidneys stop excreting phosphate properly, so it accumulates. High phosphate drives bone disease and vascular calcification, and it disturbs the calcium and parathyroid hormone system. Binders are taken with food and bind phosphate in the gut so less is absorbed. They come as calcium-based products such as calcium acetate, and non-calcium products such as sevelamer and lanthanum, plus iron-based options that also treat iron deficiency. The choice depends on your calcium level, your vascular calcification risk and what you can tolerate. Timing with meals is what makes them work, which is the detail most commonly got wrong.
Potassium binders
Reduced filtration means potassium can build up, and high potassium is one of the few genuinely emergency problems in kidney disease because of its effect on heart rhythm. The older resins, calcium and sodium polystyrene sulfonate, are still used. Newer agents, patiromer and sodium zirconium cyclosilicate, are better tolerated and are increasingly used specifically so that people can stay on the kidney-protective drugs that raise potassium rather than being forced off them. That last use is a good illustration of the priorities: a medicine is being added not to improve any number but to protect access to a treatment that works.
Sodium bicarbonate for acidosis
The kidney normally excretes acid. As function falls, acid accumulates, showing up as a low bicarbonate on blood tests. Chronic metabolic acidosis contributes to muscle loss, bone disease and possibly faster kidney decline, and oral sodium bicarbonate is used to correct it. Some studies have suggested that correcting acidosis slows progression, though the evidence is not as strong as for the protective drug classes, and the sodium load has to be weighed against blood pressure and fluid retention. It is a prescribed treatment guided by blood results, not a supplement to buy.
Treatments for anaemia
Kidneys produce erythropoietin, the hormone that tells bone marrow to make red cells. As kidney tissue is lost, production falls and anaemia develops, which is a common reason people with kidney disease feel exhausted and breathless. Iron is corrected first, often intravenously because oral iron is poorly absorbed in this setting. If anaemia persists, erythropoiesis-stimulating agents such as epoetin and darbepoetin are used. Targets are deliberately kept moderate rather than aiming for a normal haemoglobin, because trials found that pushing levels up too far increased strokes and cardiovascular events. A newer oral class, the hypoxia-inducible factor prolyl hydroxylase inhibitors, is available in some countries.
Bone, mineral and other supportive treatment
Active vitamin D analogues and calcimimetics are used to manage the overactive parathyroid gland that develops in advanced kidney disease. Diuretics manage fluid overload and contribute to blood pressure control. Allopurinol treats gout, which is more common when urate clearance falls, although trials testing urate lowering specifically to slow kidney decline did not show the hoped-for benefit, and that negative result is worth knowing because urate-lowering is still sometimes promoted as kidney protection.
None of these lowers creatinine. Several will not change any number you were originally worried about. They are prescribed because they prevent fractures, heart rhythm problems, exhaustion and hospital admissions, which is what living well with reduced kidney function actually depends on. If your filtration is already substantially reduced, creatinine levels in stage 3 kidney disease and the levels that indicate kidney failure explain where these treatments usually enter the picture.
Drugs to avoid, or to use with more care than usual
Protecting kidney function is at least as much about what you stop taking as what you start. Nothing in this section is an instruction to stop a prescribed medicine, because some of these drugs are appropriate and necessary in specific circumstances. It is a list of things to raise with the person who prescribes for you.
Anti-inflammatory painkillers. Ibuprofen, naproxen, diclofenac and the rest. They constrict the vessel entering the filtering unit and reduce filtration, and they are bought without prescription for everyday aches by people who do not think of them as medication. Regular long-term use is among the most common avoidable contributors to reduced kidney function, and the risk rises sharply alongside a diuretic and an ACE inhibitor or ARB. Ask what you should use for pain instead.
Proton pump inhibitors used indefinitely. Omeprazole and similar drugs are linked to interstitial nephritis and, in observational data, to chronic kidney disease. They are useful medicines with clear indications. The problem is repeat prescriptions that run for years without anyone reviewing whether they are still needed.
Certain antibiotics. Aminoglycosides such as gentamicin are directly toxic to kidney tubules and are used with monitoring for that reason. Others, including vancomycin, need dose adjustment by kidney function. This is one of the clearest examples of why an accurate filtration estimate matters, a topic covered in creatinine clearance and drug dosing.
Iodinated contrast for scans. The risk to kidneys from modern contrast has been revised downward considerably and is smaller than once believed, but it is not zero in advanced kidney disease. The scan is often still the right decision. Make sure the team ordering it knows your kidney function.
High-dose vitamin C. Large doses are metabolised to oxalate, which can deposit in the kidney and cause damage. This is a documented harm from a supplement widely assumed to be harmless at any dose.
Creatine supplements, for a different reason. They raise the creatinine reading through increased production rather than by harming kidneys, but the reading is indistinguishable from early impairment on a lab report. If you take creatine, say so, and read whether creatine increases creatinine for the detail.
Anything bought online for kidney health. Covered at length below, and the reason it appears here as well is that unregulated products are a documented cause of kidney injury rather than a neutral waste of money.
Two practical habits do more good than any of the individual points. Keep a current list of everything you take, including supplements and things bought over the counter, and bring it to appointments. And ask specifically about sick-day rules: which medicines should be paused temporarily if you become dehydrated through vomiting or diarrhoea. People with reduced kidney function who have never been given that advice are missing something genuinely useful.
The supplement market: what is sold and what it is worth
Search the phrase this article is named after and you will find products, not pharmacology. Capsules, powders, teas and multi-week programmes, sold with before-and-after lab reports and testimonials, promising to bring creatinine down naturally. The market is large, largely unregulated, and aimed at people who have just been told something frightening and want to do something about it. That is an understandable impulse, and it is exactly the impulse the marketing is built around.
Here is what is actually sold, and what the evidence supports.
| Product | Typical claim | What the evidence shows |
|---|---|---|
| Astragalus | Improves kidney function and reduces creatinine | Small, mostly low-quality trials with inconsistent methods. Not enough to support use, and interactions with immunosuppressants are a concern. |
| Cordyceps preparations | Restores kidney function | Limited small studies, poor blinding, no adequate long-term outcome data. Product content varies widely between manufacturers. |
| Rhubarb root extracts | Lowers urea and creatinine | Some small studies, mainly from one region, with methodological limitations. Anthraquinone content raises safety questions with prolonged use. |
| Nettle, dandelion, parsley teas | Flushes toxins, cleanses kidneys | Mild diuretic effect at most. No evidence of improved filtration. Potassium content is a genuine problem in advanced kidney disease. |
| Chanca piedra | Dissolves stones, protects kidneys | Some interest in stone prevention; no credible evidence for improving filtration or lowering creatinine. |
| Turmeric and curcumin | Anti-inflammatory kidney protection | Plausible laboratory rationale, weak clinical evidence, and high oxalate content in turmeric is a concern for stone formers. Covered in turmeric and creatinine. |
| Magnesium supplements | Lowers creatinine | No evidence for lowering creatinine, and magnesium accumulates when kidney function is reduced. See whether magnesium lowers creatinine. |
| Oral carbon adsorbents | Adsorb uraemic toxins in the gut | An actual pharmaceutical approach, used in some countries. Large international trials did not show that it delayed dialysis, which is a useful example of a plausible idea failing a proper test. |
| Keto acid analogues | Support a low-protein diet | A legitimate prescribed adjunct to a supervised low-protein diet in advanced disease, not a creatinine-lowering supplement, and not something to self-manage. |
A pattern runs through that table. Where evidence exists at all it is small, short, poorly blinded and often unreplicated. Where a plausible idea has been tested properly, as with the carbon adsorbents, it has generally failed to deliver. And several of these products carry specific risks in exactly the population buying them, because a kidney that cannot excrete potassium, magnesium or phosphate normally turns a harmless herbal tea into a real hazard.
There is also a mechanical trick worth naming. Anything with a diuretic effect makes you urinate more. Drink less and pass more, and a spot creatinine can shift a little without any change in filtration whatsoever. Products sold on a two-week before-and-after comparison exploit exactly this kind of normal variation, which is one reason the idea of lowering creatinine overnight is so widely sold and so rarely meaningful.
Herbal and traditional products that have damaged kidneys
This section is not about products being useless. It is about products causing irreversible kidney failure and cancer, which has happened repeatedly and is well documented in the medical literature.
Aristolochic acid
Aristolochic acid occurs naturally in plants of the Aristolochia genus, used in various traditional preparations. In the early 1990s a cluster of young women in Belgium developed rapidly progressive kidney failure after attending a slimming clinic where a herbal preparation had been substituted with an Aristolochia species. Many reached dialysis or transplantation within a few years. A striking number went on to develop cancer of the upper urinary tract.
The mechanism is now well understood. Aristolochic acid causes progressive scarring of the tissue between the kidney tubules, and it forms adducts with DNA that produce a characteristic mutation pattern in urothelial cells. The same agent has been implicated in Balkan endemic nephropathy, a regional kidney disease long linked to contamination of wheat with Aristolochia clematitis seeds. It is classified as carcinogenic to humans, and its damage is not reversible.
Regulators in many countries have banned it. That does not make it absent, because online sales cross borders, plant names are inconsistent between traditions and languages, and substitution of one plant for a similar-sounding one is common in unregulated supply chains. Contamination of a product that does not list it as an ingredient is precisely the documented pattern of harm.
The most dangerous irony in this whole area: a product bought to lower creatinine can raise it permanently. Aristolochic acid nephropathy typically presents as progressive kidney failure with only modest protein in the urine, and by the time it is recognised the scarring is established. Anyone who has taken an unidentified herbal preparation and then developed unexplained kidney impairment should tell their doctor exactly what was taken and where it came from.
Ayurvedic and other traditional preparations
Ayurvedic medicine has a long history and a substantial body of practice behind it, and it is not the tradition that is the issue here. It is the products, particularly those bought online without any oversight of what is in them.
Two distinct problems are documented. The first is heavy metal contamination. Independent testing of ayurvedic products purchased in Western markets and over the internet has repeatedly found lead, mercury and arsenic, sometimes at levels far above safety limits. The second problem is deliberate rather than accidental: within one branch of the tradition, known as rasa shastra, metals including mercury and lead are intentionally incorporated after processing that practitioners hold to render them safe. Products from this branch have been associated with clinically significant lead poisoning in published case reports and public health investigations.
Lead itself causes kidney damage. So a preparation marketed for kidney disease can carry a nephrotoxin as an undisclosed or deliberately included ingredient. Cases of lead poisoning traced to imported traditional remedies appear regularly in the medical literature and in public health alerts from national agencies.
Other traditional systems carry their own documented issues, from undeclared pharmaceutical adulterants such as steroids and anti-inflammatory drugs, to plants that are genuinely nephrotoxic, to enormous variability in what is actually inside a capsule. Where a proprietary polyherbal formulation is sold specifically for high creatinine, there is usually no published trial of that exact formulation at all, only claims built on the reputation of individual ingredients.
Why “natural” is not a safety argument
Plants make chemicals for their own purposes, and some of them are among the most potent toxins known. The kidney concentrates what passes through it, which is precisely why it is vulnerable to substances that other organs tolerate. A pharmaceutical goes through toxicology testing, controlled trials, dose-finding, manufacturing standards and post-marketing surveillance. A capsule bought online has been through none of that, and in many jurisdictions it can be sold without anyone verifying its contents before it goes to market.
That asymmetry matters most for someone whose kidney function is already reduced, because the safety margin has narrowed. Substances that healthy kidneys clear without difficulty accumulate. Potassium that a normal kidney excretes easily builds toward levels that affect heart rhythm. The population most attracted to these products is the population least able to tolerate them.
Changes to protein intake, salt, fluids and blood pressure control do genuine work, and none of it involves buying anything. Lowering creatinine naturally and preventing creatinine from rising cover what actually helps.
How to judge any product that claims to lower creatinine
You do not need a medical degree to assess these claims. You need a small number of questions, and most products fail on the first one.
Ask which trial, in which journal, in how many people, over what period, and compared against what. A genuine claim survives those five questions. Marketing claims almost never do. “Clinically proven” is not a regulated phrase and can be printed on anything.
Creatinine varies week to week with hydration, diet, exercise and the laboratory’s own analytical variation. Selecting the results that fell and showing those is trivially easy and proves nothing. You are never shown the people whose numbers went up or who stopped taking it.
Traditional use tells you a plant was used, not that it worked or that it was safe. Plenty of long-standing traditional treatments turned out to be inert, and several turned out to be poisonous. Longevity of a practice is not evidence of effect.
These are deliberately unfalsifiable phrases, chosen precisely because they are permitted where a medical claim would not be. They commit to nothing measurable, so they cannot be wrong and they cannot be checked.
The most harmful claim in the category. Someone who delays real treatment because a product promised reversal loses time that cannot be recovered. Scarred filtering units do not regenerate, and nothing sold online changes that. Read whether creatinine can be cured for why the framing itself is wrong.
Aristolochic acid is entirely natural and causes irreversible kidney failure and urinary tract cancer. Any seller using this argument has told you they either do not understand toxicology or are not interested in it.
Named molecule, published trials with hard outcomes, known side effects, monitoring schedule, regulatory approval, and a clinician accountable for the decision. That is the standard everything else should be measured against, and it is not an unreasonably high bar.
Three further checks are worth applying to anything you are considering. Does the seller ask you to stop or reduce a prescribed medicine? That alone is enough to walk away, and it is a recurring feature of the more predatory operations. Does the price scale with desperation, with escalating multi-month programmes? Does anyone selling it have a qualification you can verify with a regulator? And whatever you conclude, tell your own doctor what you are taking, because interactions with kidney medicines are real and a clinician cannot account for what they do not know about.
What success actually looks like
Because the goal has been reframed several times on this page, it is worth setting out plainly what a good outcome looks like, so you can tell whether treatment is working.
Obstruction relieved, a nephrotoxic drug withdrawn, dehydration corrected, an infection treated. This is the scenario where creatinine genuinely falls, sometimes within days, and it is the reason the first response to a rise is investigation rather than treatment.
In inflammatory kidney disease treated before scarring is established, function can improve substantially. This depends on an accurate diagnosis, often requiring a biopsy, and on specialist treatment.
The most common definition of success in chronic kidney disease. The creatinine does not fall, but it stops climbing at the rate it was, and the projected date of needing dialysis moves years further away. This is what the protective drug classes deliver.
Potassium, phosphate, haemoglobin, bicarbonate and blood pressure all held in acceptable ranges. This is what determines how you feel day to day, and it is largely independent of the creatinine value.
Since heart disease is the more likely cause of harm in most people with reduced kidney function, blood pressure, cholesterol, glucose and smoking get as much attention as the kidney itself.
A creatinine that has been stable for three years in someone with established kidney disease is a success story, even though nothing on the report has improved. That framing is unsatisfying if you came looking for a number to move. It is also the truth, and it is what your nephrologist is working towards. How to lower creatinine levels covers the realistic levers in more depth, and when to worry about creatinine levels explains which changes warrant concern.
What to actually ask your doctor
The most useful thing this page can give you is a set of questions that turn a rushed appointment into a productive one. Take these written down.
What is my eGFR, and what has it been over the last few years? The trend matters more than today’s value, and old results are usually available. Ask whether the decline is faster than expected for your age.
Do I have protein or albumin in my urine, and what is the ratio? Albuminuria drives both prognosis and treatment choice. If it has never been checked, ask why.
What do you think is causing this? Treatment follows the cause. If the cause is unclear, ask what would be needed to establish it and whether it would change management.
Should I be on an ACE inhibitor or ARB, and if not, why not? There are legitimate reasons not to be, including high potassium, low blood pressure or previous intolerance. Hearing the reason is more useful than assuming an oversight.
Would an SGLT2 inhibitor be appropriate for me? The indications have widened considerably and now extend well beyond diabetes. This is a reasonable question in chronic kidney disease with albuminuria.
Is anything on my current list harming my kidneys? Bring everything, including over-the-counter painkillers, supplements and anything bought online. This single question resolves a meaningful proportion of unexplained rises.
What should I expect my creatinine to do on this treatment, and when? Asking in advance prevents an expected rise from being mistaken for deterioration, and it tells you what an unexpected result would look like.
Do I need sick-day rules? Which medicines to pause during vomiting, diarrhoea or fever, and when to restart. Many people who should have this advice have never been given it.
Should I see a nephrologist? Referral criteria exist and depend on filtration, albuminuria and rate of decline. Asking whether you meet them is entirely legitimate.
What symptoms should make me seek urgent help? Ask for the specific list relevant to you, and make sure it covers a marked drop in urine output, new swelling, breathlessness, confusion and persistent vomiting.
The NIDDK guidance on kidney disease tests and diagnosis is a reasonable primer to read before that appointment, and MedlinePlus on the creatinine test explains what the measurement itself involves.
The Waldev creatinine clearance calculator turns your creatinine into an estimated clearance for your age, sex and weight, which is a far more useful starting point for a conversation than the raw number. It sits alongside the rest of the Waldev health calculators.
Related reading across the cluster: what creatinine clearance means, creatinine clearance versus GFR, what causes high creatinine, and the full creatinine article library.
Best medicine to reduce creatinine: frequently asked questions
What is the best medicine to reduce creatinine?
No medicine exists whose purpose is lowering creatinine, and no drug is approved for that indication anywhere. What kidney specialists prescribe are medicines that protect kidney function: ACE inhibitors or ARBs, SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists such as finerenone, and in some cases GLP-1 receptor agonists. These slow the loss of filtration, which is what stops creatinine climbing. The right combination depends on your cause, your kidney function, your potassium and your other conditions, so the decision belongs with your own doctor rather than a general article.
Can any tablet bring high creatinine back to normal?
Only when a reversible cause is treated. Relieving an obstruction, withdrawing a drug that is causing injury, correcting dehydration or treating an infection can all bring creatinine down substantially, sometimes within days. Where kidney tissue has already scarred, no tablet restores it, because filtering units do not regenerate once lost. Treatment in that situation aims to stop further loss rather than recover what has gone. Any product promising to return an established raised creatinine to normal is making a claim medicine cannot currently support.
Why did my creatinine go up after starting a kidney medicine?
Because several kidney-protective drugs work by lowering the pressure inside the filtering units, which slightly reduces filtration in the short term. ACE inhibitors, ARBs and SGLT2 inhibitors all typically cause a small early rise that then plateaus, and that pattern is expected rather than harmful. What it buys is less protein leak and slower scarring over years. A large or continuing rise is different and needs assessment. Never stop a prescribed medicine on the basis of one result; ask the prescriber what the expected pattern was.
Do ayurvedic or herbal medicines reduce creatinine?
There is no reliable evidence that they do, and there is solid evidence that some cause serious harm. Aristolochic acid, present in some traditional preparations, causes irreversible kidney failure and urinary tract cancer. Independent testing of ayurvedic products bought online has repeatedly found lead, mercury and arsenic, and lead itself damages kidneys. Products in this market are largely unregulated, so contents vary and contamination is documented. If you take anything of this kind, tell your doctor exactly what it is and where it came from.
Are ACE inhibitors good or bad for creatinine?
Both, depending on the timescale, which is why they are so often misunderstood. In the first weeks they usually raise creatinine slightly by reducing pressure inside the filter. Over years they slow the decline in kidney function and reduce protein in the urine, which is why they have been standard treatment in proteinuric kidney disease for three decades. Potassium and kidney function are monitored after starting or increasing them, and they are often paused during dehydrating illness. Whether one suits you is a decision for your prescriber.
What do SGLT2 inhibitors do for kidney disease?
They block glucose and sodium reabsorption in the kidney tubule, which triggers a reflex that lowers pressure inside the filtering unit. Large randomised trials in chronic kidney disease, in people with and without diabetes, have shown slower progression, fewer people reaching kidney failure, and reduced cardiovascular death. They cause a small early dip in filtration that recovers, so an early creatinine rise is expected. Risks include genital fungal infections, volume depletion and, in diabetes, ketoacidosis at normal glucose levels. Suitability depends on your individual circumstances.
Is there a medicine to avoid dialysis?
There is no medicine that guarantees it, but treatment can move the timeline substantially. Protective drug classes slow the rate of decline, and slowing it enough can put dialysis years further away or beyond a person’s lifetime. That is a real achievement and is what modern kidney treatment aims at. Products advertised specifically as dialysis-avoidance cures are the most dangerous in this market, because delaying proper treatment costs function that cannot be recovered. Discuss the realistic trajectory with a nephrologist rather than with a seller.
Do phosphate and potassium binders lower creatinine?
No, and they are not intended to. Binders treat the consequences of reduced filtration rather than the filtration itself. Phosphate binders reduce phosphate absorption from food, protecting bone and blood vessels. Potassium binders lower potassium, which is important because high potassium can cause dangerous heart rhythms, and because they often allow people to continue kidney-protective drugs that would otherwise have to be stopped. Both are prescribed on the basis of blood results and taken according to specific instructions, particularly around meal timing for phosphate binders.
Should I stop my blood pressure tablets if creatinine is high?
Not on your own, and usually not at all. Blood pressure control is one of the most effective ways to protect remaining kidney function, and the drugs most likely to cause a small creatinine rise are frequently the ones providing the most protection. There are situations where a temporary pause is right, such as during illness with vomiting or diarrhoea, and that is exactly what sick-day rules cover. Ask your prescriber for those rules in advance so you know what to do when you are unwell.
What symptoms mean I should seek urgent medical help?
Passing much less urine than usual or none at all, new or rapidly worsening swelling of the legs, face or abdomen, breathlessness particularly when lying flat, confusion or unusual drowsiness, persistent vomiting, chest pain, or an irregular heartbeat that may indicate high potassium. Severe muscle pain with dark cola-coloured urine also needs urgent assessment. These symptoms are about kidney function and its complications rather than the creatinine number itself, and they warrant immediate care rather than waiting for the next scheduled appointment.
The short version
There is no best medicine to reduce creatinine, because no drug is designed to do that and one that did would be dangerous. What exists are medicines that protect kidney function: ACE inhibitors and ARBs, SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists, GLP-1 receptor agonists in type 2 diabetes, and statins for the cardiovascular risk that accompanies kidney disease. Several of them raise creatinine slightly at first and are still the right treatment, which is the clearest demonstration that chasing the number misleads. Alongside these sit medicines for the complications, which change how you feel without changing the marker at all.
Treat the supplement market with suspicion. Where evidence exists it is weak, several products are hazardous in reduced kidney function, and aristolochic acid and heavy metal contamination have caused irreversible harm. Judge any product by the questions in the section above, tell your doctor everything you take, and use the CrCl calculator to put your own result in context. More across the health blog and the wider tool library at waldev.com.
Medical disclaimer: This article is general educational information about medicines used in kidney disease. It is not medical advice, contains no dosing information by design, and must never be used to start, stop or change any treatment. Every drug mentioned has specific indications, contraindications, monitoring requirements and interactions that depend on your individual kidney function, potassium, blood pressure and other conditions. Only a doctor who knows your full history can decide what is appropriate for you. Discuss your results and your medicines with your own clinician, and seek urgent medical attention for markedly reduced urine output, new swelling, breathlessness, confusion or persistent vomiting.
MedlinePlus explains what the creatinine test measures, how it is done and how results are used. Creatinine test explained →
NIDDK on the blood and urine tests used to assess kidney disease and guide treatment decisions. CKD tests & diagnosis →
The National Kidney Foundation on eGFR, what the ranges mean, and how the stages are defined. Estimated GFR explained →